Chelsea Kotch1,2, Robert Avery1,3,2, Kelly D Getz2, Eric Bouffet4, Peter de Blank5, Robert Listernick6, David H Gutmann7, Miriam Bornhorst8, Cynthia Campen9, Grant T Liu3, Richard Aplenc2, Yimei Li10,2, Michael J Fisher1,2. 1. Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 2. University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. 3. Division of Ophthalmology, Department of Surgery, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 4. Division of Haematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. 5. Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. 6. Division of Advanced General Pediatrics, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. 7. Department of Neurology, Washington University School of Medicine, St Louis, Missouri, USA. 8. Department of Pediatric Hematology-Oncology, Children's National Hospital, Washington DC, USA. 9. Department of Neurology, Stanford University, Palo Alto, California, USA. 10. Department of Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract
BACKGROUND: Nearly one-third of patients with neurofibromatosis type 1-associated optic pathway glioma (NF1-OPG) fail frontline chemotherapy; however, little is known about risk factors for treatment failure. METHODS: We performed a retrospective multi-institutional cohort study to identify baseline risk factors for treatment-refractory/relapsed disease and poor visual outcome in children with NF1-OPG. Refractory/relapsed NF1-OPG was defined as a requirement of two or more treatment regimens due to progression or relapse. RESULTS: Of 111 subjects eligible for inclusion, adequate clinical and visual data were available for 103 subjects from 7 institutions. Median follow-up from the initiation of first chemotherapy regimen was 95 months (range 13-185). Eighty-four (82%) subjects received carboplatin-based frontline chemotherapy. Forty-five subjects (44%) experienced refractory/relapsed disease, with a median time of 21.5 months (range 2-149) from the initiation of first treatment to the start of second treatment. The proportion of patients without refractory/relapsed disease at 2 and 5 years was 78% and 60%. In multivariable analyses, age less than 24 months at initial treatment, posterior tumor location, and familial inheritance were associated with refractory/relapsed NF1-OPG by 2 years. Both age less than 24 months and posterior tumor location were associated with refractory/relapsed NF1-OPG by 5 years. Subjects with moderate to severe vision loss at last follow-up were more likely to have posterior tumor location, optic disc abnormalities, or abnormal visual acuity at initial treatment. CONCLUSION: Young age, posterior tumor location, and optic disc abnormalities may identify patients with the greatest likelihood of refractory/relapsed NF1-OPG and poor visual outcomes, and who may benefit from newer treatment strategies.
BACKGROUND: Nearly one-third of patients with neurofibromatosis type 1-associated optic pathway glioma (NF1-OPG) fail frontline chemotherapy; however, little is known about risk factors for treatment failure. METHODS: We performed a retrospective multi-institutional cohort study to identify baseline risk factors for treatment-refractory/relapsed disease and poor visual outcome in children with NF1-OPG. Refractory/relapsed NF1-OPG was defined as a requirement of two or more treatment regimens due to progression or relapse. RESULTS: Of 111 subjects eligible for inclusion, adequate clinical and visual data were available for 103 subjects from 7 institutions. Median follow-up from the initiation of first chemotherapy regimen was 95 months (range 13-185). Eighty-four (82%) subjects received carboplatin-based frontline chemotherapy. Forty-five subjects (44%) experienced refractory/relapsed disease, with a median time of 21.5 months (range 2-149) from the initiation of first treatment to the start of second treatment. The proportion of patients without refractory/relapsed disease at 2 and 5 years was 78% and 60%. In multivariable analyses, age less than 24 months at initial treatment, posterior tumor location, and familial inheritance were associated with refractory/relapsed NF1-OPG by 2 years. Both age less than 24 months and posterior tumor location were associated with refractory/relapsed NF1-OPG by 5 years. Subjects with moderate to severe vision loss at last follow-up were more likely to have posterior tumor location, optic disc abnormalities, or abnormal visual acuity at initial treatment. CONCLUSION: Young age, posterior tumor location, and optic disc abnormalities may identify patients with the greatest likelihood of refractory/relapsed NF1-OPG and poor visual outcomes, and who may benefit from newer treatment strategies.
Authors: Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery Journal: J Neuroophthalmol Date: 2017-09 Impact factor: 3.042
Authors: L J Balcer; G T Liu; G Heller; L Bilaniuk; N J Volpe; S L Galetta; P T Molloy; P C Phillips; A J Janss; S Vaughn; M G Maguire Journal: Am J Ophthalmol Date: 2001-04 Impact factor: 5.258
Authors: R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett Journal: J Neurosurg Date: 1997-05 Impact factor: 5.115
Authors: Kelly A Diggs-Andrews; Jacquelyn A Brown; Scott M Gianino; Joshua B Rubin; David F Wozniak; David H Gutmann Journal: Ann Neurol Date: 2014-02-06 Impact factor: 10.422
Authors: Amedeo A Azizi; David A Walker; Jo-Fen Liu; Astrid Sehested; Timothy Jaspan; Berthold Pemp; Ian Simmons; Rosalie Ferner; Jacques Grill; Darren Hargrave; Pablo Hernáiz Driever; D Gareth Evans; Enrico Opocher Journal: Neuro Oncol Date: 2021-01-30 Impact factor: 12.300